Solar-Powered Device Affordable, Reliable Tool to Measure Blood Pressure

A new solar powered, automated blood pressure monitoring device was equally accurate as the standard device that measures systolic blood pressure

The device was favored by health professionals and patients when tested in Africa

The new device eliminates the need for batteries, which are expensive and scarce in low economic settings

DALLAS, Nov. 8, 2010 /PRNewswire-USNewswire/ -- A new solar-powered device to measure blood pressure may help slow the worldwide increase in cardiovascular disease by providing affordable and reliable blood pressure testing in low income countries, according to research published in Hypertension: Journal of the American Heart Association.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100222/AHSALOGO)

(Logo: http://photos.prnewswire.com/prnh/20100222/AHSALOGO)

The solar powered device — 94 percent in agreement with the standard blood pressure testing method for systolic blood pressure — is in field testing in Uganda and Zambia, Africa.

"The incidence of hypertension is rising dramatically in these countries," said Eoin O'Brien, M.D., lead author of the study and professor in Conway Institute of Biomolecular and Biomedical Research at the University College Dublin in Belfield, Dublin, Ireland. "Hypertension leads to stroke and heart attack as the major cause of death around the world. It is greater than malnutrition, cancer and AIDS."

Many low-income countries have a short supply of trained medical personnel, he said. "We have been able to provide an accurate, robust and inexpensive device to diagnose high blood pressure. It's a start. If we can't measure blood pressure, we certainly can't begin to treat hypertension."

The World Health Organization asked multiple companies to devise a blood pressure measuring device that was accurate, easy to use and solar powered. One device met their criteria. After initial testing showed the accuracy of the selected device, it was used in two centers in Uganda and one center in Zambia. Staff, trained on the fully automated device in about 15 minutes, took blood pressure readings on about 716 participants, using the new device and a standard one. They repeated the effort one month later. Both patients and healthcare professionals preferred the new device:

• Eighty-five percent of healthcare professionals rated the solar device as good or very good primarily because of ease of use (88 percent) and the automated features (85 percent).
• Seventy-nine percent considered the solar device an advantage over the standard device.
• The majority of healthcare providers rated it best for its comfort, clearly legible readings, the cuff and the on/off switch.
• After the first and final visit a month later for patient blood pressure readings, 97 percent of healthcare professionals favored the new device and would recommend its use.

"Solar energy eliminates the need for expensive rechargeable batteries in remote areas where electricity and the availability of batteries might be scarce, but sunlight is plentiful," O'Brien said. "It can be run on batteries, but it can also be left in the sunlight to charge, making it ideal for rural areas and use out in the bush."

The device costs about $32 (25 Euro), with significant savings from not having to provide and use batteries regularly, he said.

While the device initially fulfilled accuracy criteria for the European Society of Hypertension, it had less accuracy for diastolic blood pressure (the pressure when the heart relaxes) on a second testing and in the study.  But it wouldn't be difficult for manufacturers to correct the device, O'Brien said. Moreover, systolic blood pressure (the pressure when the heart contracts) is the major contributor to cardiovascular events. "Systolic blood pressure is the blood pressure reading on which most decisions are made," O'Brien said.

Manufacturers of other devices, such as those used to record or measure blood sugar, cholesterol and electrocardiograms (ECG), might also be encouraged to fulfill the requirements of low income countries, he said. "We now hope to use the solar device to diagnose hypertension in pregnancy as a step towards reducing the very high maternal death rates from this illness in low income countries."

Co-authors are: Gianfranco Parati, M.D.; Michael Ochan Kilama, M.D.; Andrea Faini, M.D.; Elisa Facelli, M.D.; Kenneth Ochen, M.D.; Cyprian Opira, M.D.; Shanthi Mendis, M.D.; Jiguang Wang, M.D.; and Neil Atkins, Ph.D. Author disclosures are on the abstract.

The World Health Organization funded the study.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

NR10-1164 (Hypertension10/O'Brien)

Editor's Note:

Visit the American Heart Association's high blood pressure Web site – www.heart.org/hbp – to learn more about high blood pressure risk factors, treatment options, side effects and success rates.

Additional resources:

• Downloadable stock footage, animation, and our image gallery are located at www.heart.org/news under Multimedia.
• Stay up to date on the latest news from American Heart Association scientific meetings, including Scientific Sessions 2010, by following us at www.twitter.com/heartnews. We will be tweeting from the conference using hashtag #AHA10News.

SOURCE American Heart Association